Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.15), $0.04 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $94.5 million versus the consensus estimate of $89.83 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.